Cancer survival reaches 70% at 5 years, as targeted and immunotherapies boost outcomes and shift care toward survivorship and long-term quality of life.
Rebecca Siegel, MPH
Advertisement
Rebecca Siegel, MPH, is a cancer epidemiologist and Senior Scientific Director of Surveillance Research at the American Cancer Society.
Articles by Rebecca Siegel, MPH
Rebecca Siegel, MPH, highlights alarming cancer disparities among American Indian, Alaska Native, and Black populations, emphasizing systemic issues over individual choices.
Recent cancer statistics reveal significant survival rate improvements for aggressive cancers, highlighting advancements in treatment and a shift in oncology outcomes.
Rebecca Siegel, MPH, reveals key insights on lung cancer trends, survival rates, and the need for targeted interventions in diverse populations.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
5